A live-attenuated RhCMV/SIV vaccine shows long-term efficacy against heterologous SIV challenge.

Sci Transl Med 2019 Jul;11(501)

Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.

Previous studies have established that strain 68-1-derived rhesus cytomegalovirus (RhCMV) vectors expressing simian immunodeficiency virus (SIV) proteins (RhCMV/SIV) are able to elicit and maintain cellular immune responses that provide protection against mucosal challenge of highly pathogenic SIV in rhesus monkeys (RMs). However, these efficacious RhCMV/SIV vectors were replication and spread competent and therefore have the potential to cause disease in immunocompromised subjects. To develop a safer CMV-based vaccine for clinical use, we attenuated 68-1 RhCMV/SIV vectors by deletion of the Rh110 gene encoding the pp71 tegument protein (ΔRh110), allowing for suppression of lytic gene expression. ΔRh110 RhCMV/SIV vectors are highly spread deficient in vivo (~1000-fold compared to the parent vector) yet are still able to superinfect RhCMV RMs and generate high-frequency effector-memory-biased T cell responses. Here, we demonstrate that ΔRh110 68-1 RhCMV/SIV-expressing homologous or heterologous SIV antigens are highly efficacious against intravaginal (IVag) SIV challenge, providing control and progressive clearance of SIV infection in 59% of vaccinated RMs. Moreover, among 12 ΔRh110 RhCMV/SIV-vaccinated RMs that controlled and progressively cleared an initial SIV challenge, 9 were able to stringently control a second SIV challenge ~3 years after last vaccination, demonstrating the durability of this vaccine. Thus, ΔRh110 RhCMV/SIV vectors have a safety and efficacy profile that warrants adaptation and clinical evaluation of corresponding HCMV vectors as a prophylactic HIV/AIDS vaccine.

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.aaw2607DOI Listing
July 2019
7 Reads

Publication Analysis

Top Keywords

siv challenge
16
rhcmv/siv vectors
16
siv
8
heterologous siv
8
Δrh110 rhcmv/siv
8
vectors
6
Δrh110
5
challenge
5
rhcmv/siv
5
rhcmv rms
4
rms generate
4
~1000-fold compared
4
superinfect rhcmv
4
compared parent
4
vector superinfect
4
parent vector
4
generate high-frequency
4
cell responses
4
68-1 rhcmv/siv-expressing
4
rhcmv/siv-expressing homologous
4

Similar Publications